• Galapagos swung to net profit of EUR 14.5 million, with basic and diluted earnings per share at EUR 0.22.
• Total net revenues fell 91% to EUR 6.5 million, while operating loss narrowed to EUR 63.7 million.
• R&D expenses dropped 83% to EUR 31 million, while net financial income climbed to EUR 77.7 million.
• Cash and financial investments totaled EUR 2.98 billion at March 31, down EUR 15.8 million during quarter.
• Company expects Gilead collaboration tied to Ouro Medicines to close in Q2 2026, with year-end 2026 cash and financial investments seen at about EUR 2 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galapagos NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605061601OMX_____CNEWS_EN_GNW1001180418_en) on May 06, 2026, and is solely responsible for the information contained therein.